transforming-growth-factor-beta and Mood-Disorders

transforming-growth-factor-beta has been researched along with Mood-Disorders* in 2 studies

Reviews

1 review(s) available for transforming-growth-factor-beta and Mood-Disorders

ArticleYear
TGF-β/Smad Signalling in Neurogenesis: Implications for Neuropsychiatric Diseases.
    Cells, 2021, 06-03, Volume: 10, Issue:6

    TGF-β/Smad signalling has been the subject of extensive research due to its role in the cell cycle and carcinogenesis. Modifications to the TGF-β/Smad signalling pathway have been found to produce disparate effects on neurogenesis. We review the current research on canonical and non-canonical TGF-β/Smad signalling pathways and their functions in neurogenesis. We also examine the observed role of neurogenesis in neuropsychiatric disorders and the relationship between TGF-β/Smad signalling and neurogenesis in response to stressors. Overlapping mechanisms of cell proliferation, neurogenesis, and the development of mood disorders in response to stressors suggest that TGF-β/Smad signalling is an important regulator of stress response and is implicated in the behavioural outcomes of mood disorders.

    Topics: Humans; Mood Disorders; Nervous System Diseases; Signal Transduction; Smad Proteins; Transforming Growth Factor beta

2021

Trials

1 trial(s) available for transforming-growth-factor-beta and Mood-Disorders

ArticleYear
Decreased levels of whole blood glial cell line-derived neurotrophic factor (GDNF) in remitted patients with mood disorders.
    The international journal of neuropsychopharmacology, 2006, Volume: 9, Issue:5

    Recent post-mortem and imaging studies provide evidence for a glial reduction in different brain areas in mood disorders. This study was aimed to test whether glial cell line-derived neurotrophic factor (GDNF), a member of transforming growth factor (TGF)-beta superfamily, in blood levels was associated with mood disorders. We measured GDNF and TGF-beta levels in whole blood in remitted patients with mood disorders [n=56; major depressive disorders (MDD) 39, bipolar disorders (BD) 17] and control subjects (n=56). GDNF and TGF-beta were assayed with the sandwich ELISA method. Total GDNF levels were significantly lower in MDD and in BD than in control subjects (MDD, p=0.0003; BD, p=0.018), while no significant difference in total TGF-beta1 or total TGF-beta2 levels was found in these groups. Our study suggests that lower GDNF levels might be involved in the pathophysiology of mood disorders, although this preliminary study has several limitations.

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antidepressive Agents; Antimanic Agents; Female; Glial Cell Line-Derived Neurotrophic Factor; Humans; Lithium Chloride; Male; Middle Aged; Mood Disorders; Transforming Growth Factor beta

2006